• Sandoz advances biosimilar portfolio with sixth major biosimilar file acceptance in less than one year

  • Sandoz is seeking approval for all indications included in the reference product’s label

  • Sandoz’ submission includes data from multiple clinical trials with over 800 patients

Holzkirchen, 24 May, 2016 – Sandoz, a Novartis division and the global leader in biosimilars, announced today that the European Medicines Agency has accepted their Marketing Authorization Application for a biosimilar to Roche’s EU-licensed …

Holzkirchen, May 23, 2016 – In the wake of the earthquake that devastated northwest Ecuador in April, Sandoz, a Novartis division, today announced that it will support the recovery effort with financial aid and a product donation.

Hundreds of people lost their lives in the earthquake, which injured thousands more, devastated communities and left approximately 25,000 people living in shelters.

Employees locally have already been actively involved in a variety of relief operations, including preparing emergency kits of food and hygiene items for delivery to the …